Core Viewpoint - Prenetics Global Ltd. has decided to abandon its Bitcoin treasury strategy to focus on its supplement brand IM8, which has shown rapid growth and reached $100 million in annualized recurring revenue within 11 months [1][2]. Group 1: Company Strategy - The CEO of Prenetics, Danny Yeung, stated that the success of IM8 has exceeded expectations, leading the management team to unanimously agree on focusing efforts on this opportunity to create sustainable shareholder value [2]. - Prenetics initially launched its Bitcoin treasury strategy in June, planning to purchase $20 million worth of Bitcoin and appointing Andy Cheung to its board [2][3]. - The company had aimed to reach $1 billion in annualized revenue and $1 billion in Bitcoin holdings, having raised $48 million from investors, including Kraken and Exodus, to support this strategy [4]. Group 2: Financial Performance - As of December 30, Prenetics reported holding $70 million in cash and 510 BTC valued at nearly $46 million [4]. - The decision to abandon the Bitcoin strategy comes amid a prolonged downturn in the cryptocurrency market, with Bitcoin prices dropping significantly from a record high of $126,000 to a low of $80,600 [5].

Core Insights - Cencora, Inc. is a significant player in the pharmaceutical distribution industry, with a market capitalization of $58.7 billion, providing a range of healthcare products and services [1][2] Company Overview - Cencora offers end-to-end pharmaceutical commercialization solutions, over-the-counter healthcare products, home healthcare supplies, and related services to healthcare providers [1] - The company is categorized as a large-cap stock due to its market cap exceeding $10 billion, highlighting its size and influence in the medical distribution sector [2] Financial Performance - In Q3, Cencora reported revenue of $80.7 billion, an increase of 8.7% year-over-year, and adjusted EPS rose by 19.8% to $4 [5] - The company has raised its fiscal 2025 adjusted EPS guidance to a range of $15.85 to $16 [5] Stock Performance - Cencora's stock has seen a year-to-date increase of 34.6% and a 27.3% rise over the past 52 weeks, outperforming the Health Care Select Sector SPDR Fund's marginal gains [4] - Despite a recent drop of 2.2% from its 52-week high of $309.35, the stock has gained 2.5% over the past three months, outperforming the XLV's 1% gain [3][4] Strategic Positioning - The company's strengths include its strategic positioning in the healthcare value chain, a diversified portfolio, and scale-driven bargaining power [2] - Cencora leverages technological capabilities in supply chain management and data analytics to achieve high operational efficiency, with fill rates exceeding 99% [2]